Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Roivant Sciences’ SEC documents can feel like wading into clinical trial protocol. Pipeline updates, cash-runway figures, and milestone payments are scattered across hundreds of pages—yet a single sentence can move ROIV’s share price. If you have ever asked, “Where do I find Roivant Sciences insider trading Form 4 transactions before the market reacts?” you know the challenge.
Stock Titan solves it. Our AI instantly parses every submission—whether a dense Roivant Sciences annual report 10-K simplified for pipeline strategy, a fresh Roivant Sciences quarterly earnings report 10-Q filing detailing R&D spend, or an urgent Roivant Sciences 8-K material events explained that discloses trial data. Interactive summaries highlight what matters: Phase III read-outs, collaboration revenue, and liquidity. You can even set real-time alerts for Roivant Sciences Form 4 insider transactions real-time to monitor executive sentiment.
Searching for specifics? Our coverage spans every form investors ask about: 10-K to see cash runway; 10-Q for quarter-over-quarter expense trends; 8-K for FDA designations; the Roivant Sciences proxy statement executive compensation for option grants; and the indispensable Roivant Sciences executive stock transactions Form 4 for ownership changes. Each document comes with plain-English notes—perfect for understanding Roivant Sciences SEC documents with AI and speeding due-diligence. Quickly generate a Roivant Sciences earnings report filing analysis, track disclosure history, or export data for models—no more CTRL-F marathons.
Whether you’re an analyst gauging dilution risk or a healthcare investor timing entry around data catalysts, our platform keeps every question answered and every filing at your fingertips—updated the moment it hits EDGAR.
Roivant Sciences (NASDAQ:ROIV) announced a new $500 million share repurchase program in addition to their previous $1.5 billion program from April 2024. The earlier program, which had $205 million remaining capacity as of March 31, 2025, has now been fully exhausted. The new repurchase program will be funded through available cash and has no expiration date.
The company maintains flexibility in executing the buyback through various methods including open market transactions, tender offers, or private negotiations. Implementation will depend on factors such as share price, market conditions, and alternative investment opportunities. The program can be suspended or discontinued at any time.
Roivant Sciences CFO Richard Pulik reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 20, 2025. The filing details the following key transaction:
- Disposed of 1,503 common shares at a price of $11.45 per share through a "net settlement" transaction (Code F)
- The transaction was related to tax withholding obligations from the vesting and settlement of previously granted RSUs
- Following the transaction, Pulik directly owns 399,056 common shares
The filing was signed by Jo Chen as Attorney-in-Fact for Richard Pulik on June 24, 2025. This routine transaction represents standard tax withholding practices for executive RSU settlements and does not indicate a discretionary sale by the insider.
Roivant Sciences (NASDAQ:ROIV) President & COO Eric Venker reported significant insider transactions on June 20, 2025. The executive exercised 100,000 stock options at $3.85 per share and subsequently sold the same number of shares at an average price of $11.45, realizing a substantial profit. Following these transactions, Venker retains direct ownership of 1,462,223 common shares and 8,238,897 stock options.
The exercised options were part of a grant made in April 2022 with a four-year vesting schedule, including a one-year cliff followed by monthly vesting over three years.
Vivek Ramaswamy, a 10% owner of Roivant Sciences, reported significant insider sales transactions in June 2025. The transactions include:
- June 18, 2025: Sold 565,266 common shares at an average price of $11.45 (range: $11.41-$11.53)
- June 20, 2025: Sold 577,007 common shares at an average price of $11.46 (range: $11.45-$11.54)
Following these transactions, Ramaswamy maintains direct ownership of 37,284,108 common shares and indirect beneficial ownership of 13,357,857 shares through spousal holdings. The total value of shares sold was approximately $13.1 million. These sales represent a notable reduction in his direct holdings but maintain his position as a significant shareholder.
Roivant Sciences Form 144 filing reveals significant insider stock sales by Vivek Ramaswamy, indicating planned disposal of 577,007 shares with an aggregate market value of $6,611,850. The sale is scheduled for June 20, 2025, through Rockefeller Financial LLC on NASDAQ.
Key transaction details:
- Securities originated as Founder Shares acquired on May 7, 2014
- Total outstanding shares: 679,806,070
- Recent trading activity shows substantial sales in past 3 months totaling 2,212,455 shares for approximately $25 million
Previous sales by Ramaswamy in the last 3 months occurred on multiple dates:
- June 18: 565,266 shares ($6.47M)
- June 6: 200,800 shares ($2.25M)
- June 4: 547,430 shares ($6.21M)
- May 7: 625,000 shares ($6.99M)
- May 6: 273,959 shares ($3.14M)
Form 144 Notice of Proposed Sale filed by Eric Venker of Roivant Sciences regarding planned sale of 100,000 common shares through Rockefeller Financial LLC, with an aggregate market value of $1,145,268.08. The shares were acquired through options exercise (grant date 4/20/2022) on 06/20/2025.
Notable recent trading activity by the same insider over the past 3 months:
- June 2-3, 2025: Sold 1 million shares for ~$11.15 million
- May 2025: Disposed of 139,148 shares for ~$1.53 million
- April 2025: Sold 110,945 shares for ~$1.13 million
- March 2025: Divested 760,945 shares for ~$8.31 million
Total shares outstanding: 679,806,070. The proposed sale represents a continuation of significant insider selling activity, with the seller disposing over 2.1 million shares in the past quarter worth approximately $22.12 million.
Vivek Ramaswamy, a key insider at Roivant Sciences, has filed Form 144 indicating a proposed sale of 565,266 common shares with an aggregate market value of $6,472,996.33. The sale is planned to be executed through Rockefeller Financial LLC on the NASDAQ exchange, with an approximate sale date of June 18, 2025.
The shares being sold originated from Founder Shares acquired on May 7, 2014, totaling 58,409,211 shares. The filing reveals significant recent selling activity by Ramaswamy over the past three months:
- June 6, 2025: 200,800 shares for $2,246,311
- June 4, 2025: 547,430 shares for $6,208,008
- May 7, 2025: 625,000 shares for $6,987,388
- May 6, 2025: 273,959 shares for $3,143,287
The company currently has 679,806,070 shares outstanding. This planned sale represents approximately 0.08% of the total outstanding shares.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
